Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Amortizatization of Intangibles (2016 - 2025)

Historic Amortizatization of Intangibles for Guided Therapeutics (GTHP) over the last 10 years, with Q3 2025 value amounting to $25000.0.

  • Guided Therapeutics' Amortizatization of Intangibles rose 1363.64% to $25000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $94000.0, marking a year-over-year increase of 1190.48%. This contributed to the annual value of $86000.0 for FY2024, which is 1315.79% up from last year.
  • Guided Therapeutics' Amortizatization of Intangibles amounted to $25000.0 in Q3 2025, which was up 1363.64% from $24000.0 recorded in Q2 2025.
  • Guided Therapeutics' Amortizatization of Intangibles' 5-year high stood at $58000.0 during Q3 2021, with a 5-year trough of $8000.0 in Q1 2021.
  • Its 5-year average for Amortizatization of Intangibles is $21333.3, with a median of $19500.0 in 2023.
  • Its Amortizatization of Intangibles has fluctuated over the past 5 years, first soared by 13200.0% in 2021, then crashed by 7068.97% in 2022.
  • Over the past 5 years, Guided Therapeutics' Amortizatization of Intangibles (Quarter) stood at $16000.0 in 2021, then rose by 12.5% to $18000.0 in 2022, then increased by 11.11% to $20000.0 in 2023, then increased by 10.0% to $22000.0 in 2024, then rose by 13.64% to $25000.0 in 2025.
  • Its Amortizatization of Intangibles stands at $25000.0 for Q3 2025, versus $24000.0 for Q2 2025 and $23000.0 for Q1 2025.